Moreover, PRAME expression has been associated with poor prognosis in solid cancers including breast cancer [23,24], sarcoma [39,40,41], head and neck cancer [42], medulloblastoma [43], uveal melanoma [32,33], and neuroblastoma [22]. Here, PRAME is linked to neuroblastoma.